2021 Webinar: PSC and Hepatic Fibrosis: An Update from the Field-PSC and Hepatic Fibrosis: An Update from the Field

Video Transcription

Video Summary

This webinar provided updates on primary sclerosing cholangitis (PSC) and hepatic fibrosis. The first speaker, Dr. Robert Hebert, discussed the role of epigenetics in cholangiocyte injury and fibrosis. He highlighted the importance of understanding the epigenetic regulation of fibrogenesis in PSC and discussed the potential for epigenetic pharmacology as a treatment option. Dr. Cynthia Levy then gave a clinical update on PSC, focusing on the challenges of drug development for this rare disease. She discussed the current management of PSC, including the use of ursodeoxycholic acid, endoscopic treatments, and surveillance for complications. She also highlighted the lessons learned from recent clinical trials, such as the Syntuzumab trial and the MGM282 trial, and discussed ongoing clinical trials exploring new treatment options for PSC. The webinar emphasized the need for better surrogate endpoints and biomarkers for clinical trials in PSC, and the importance of collaboration between researchers and patient advocacy groups like PSC Partners Seeking a Cure.

Meta Tag

Speaker Novita Lee

Topic TGIF

Keywords

primary sclerosing cholangitis

hepatic fibrosis

epigenetics

cholangiocyte injury

fibrogenesis

drug development

clinical trials

surveillance

biomarkers

Novita Lee

TGIF